Defensive · 56 dossiers

The 2026-08-04 spectrum re-rating gap has largely round-tripped: $106.35 close, then $99.41, $100.32 and $99.26 through 2026-08-07, heaviest volume on the down day. The 1.0M-share dilution vote passed on 2026-08-04; the 2026-08-11 Q1…

Relief bounce off the broker-liability selloff stalled: LSTR closed $183.09 on 2026-08-07 after $181.62 on 08-04, below the 50-day at $205.13 and above a rising 200-day at $166.56. DAT dry van and flatbed have fallen two straight weeks to…

Butterfly Embedded chip-licensing story got marquee validation — Midjourney's up-to-$74M/5yr full-body scanner on 40 Ultrasound-on-Chip modules (2026-06-18) plus 2nd partner Aleph Neuro (2026-06-25). Fundamentals still accelerating, but…

Oral STAT6 degrader (KT-621) re-rated on early BROADEN2 enrollment (6/25) and the $10.9B AbbVie–Apogee read-through, but the analyst upgrade cycle topped with RBC's 7/13 downgrade to neutral and the binary topline is 2H-2026 — a maturing,…

Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs — SPY003 IL-23 Part A (guided mid-2026,…

Post-data digestion, not acceleration: the 92% ORR combo print is fully paid for and the tape has faded from $32.90 to ~$27.7, below the $30.00 June secondary. Sell-side keeps marking up (JPM Overweight $46 on 7/15, Mizuho $40 on 7/17)…

Q2 (07-16) missed at $2.12 vs $2.25 and management cut the FY alumina outlook on Pinjarra refinery problems — five sell-side target cuts in nine sessions (BMO $55, JPM $52, WF $71), zero raises. The Hormuz premium is gone, the next…

Edge-AI silicon small-cap re-rating on Roth Capital's 2026-07-14 Buy initiation at a Street-high $125 PT, which re-opens upside above the spent $70 Needham/UBS cluster. But the last confirmed tape is the 2026-06-05 -12% distribution day,…

Professional-services roll-up re-rating: from a $16.00 IPO on 2025-12-17 to a $47.33 close on 2026-07-31, powered by the 2026-05-12 guidance raise to $980M–$1.0B FY2026 revenue. Price is discovered on a 10.90M-share float with a fifth to a…

Cyclical-bottom bounce off the $69.69 200-day (7/16 low $68.95) has firmed price into the low-mid $70s, but ATKR sits below its $78 50-day with the Street uniformly at Hold (0 Buy/3 Hold/0 Sell) into a binary 2026-08-04 Q3 print. A base…

Aurora shipped its scale-readiness milestone — second-gen International LT trucks with the safety driver removed (2026-07-22) — and the tape sold it, breaking the ~$6.00 base to ~$5.83 into a confirmed 2026-07-29 Q2 print. Good news, no…

TAVR disruptor whose de-risking catalysts (CMS CED, first US patients, French ANSM clearance) are now exhausted; price faded ~11% off the ~$11.06 high back onto the in-the-money $250M ATM near $9. No 30-day data binary — PARADIGM readout…

Post-miss +46% V-recovery has rolled over — ~$44 from a ~$48.75 June high, never retesting the $53.53 ATH. The tell: fresh $500M buyback authority funded by the June 19 €900M notes landed and the stock still faded. S&P cut the outlook to…

The 2026-08-04 Q3 print resolved the binary against the margin case: adjusted EBITDA margin 13.7% vs the ~16% guide, and FY26 EBITDA cut to $275–295M from $315–335M even as the sales guide rose. Demand held, profitability did not. Price…

Drive-thru coffee comps re-accelerating (Q1 +8.3%, FY guide raised) and the sell-side is now catching up — Stephens initiated Overweight $80, Morgan Stanley to $88 in mid-July. But June's run to ~$72 cooled to the mid-$60s, and the…

The margin-inflection leg broke at its own catalyst: Q2 (2026-07-29) adjusted OR 95.9% vs 94.6% PY — second straight quarter of YoY deterioration — revenue $332.9M missed $340.4M, and Stephens cut its 23-day-old target to $54 on 07-31.…

CGM leader's recovery has aged from catalyst-pop to an analyst-revision grind — Mizuho $90 (7/15), Truist $87 (7/16) into a ~7% two-day pop to $76.65 — but price is high-$70s still under the 200-EMA and the confirmed July 30 Q2 print is…

European winter gas-security theme re-accelerating; Equinor, the swing Norwegian pipeline supplier, held ~$40 through a Q2 double-miss on a $1.125B buyback bid. But at ~$40.31 (2026-07-24) it trades above the entire sell-side PT range (avg…

Freshly de-SPAC'd solid-state battery name has fully unwound its debut mania — down ~78% from the $25.33 ATH to ~$5.67, breaking clean through the former $9.26 floor into a fresh 52-week low at $4.24. Cantor's $18 target now sits ~217%…

Narrative and price have fully decoupled: FLY stacked a $144M CLPS award, a Moon BASE seat and a $13M Mars subcontract into a -47% drawdown, falling 9.6% on 7/16 on the awards headline itself. At $19.27 vs a $45 IPO price and 31% below the…

Tariff-driven HRC steel prices at multi-year highs powered record FY2026 (EPS $2.76, sales +46%); FRD hit an all-time-high close $37.42 on 2026-06-18 and was flagged overbought the same day. The narrative is maturing and priced near the…

Mature-node foundry re-rating into a silicon-photonics/quantum-foundry story; partnership cadence still compounding (SEALSQ PQC MoU 2026-07-08). But a fresh entry now buys above the ~$79.72 consensus target, near the $92.55 52w high,…

Tariff-refund windfall re-rating: a $25.8M IEEPA refund and a dividend raise to $0.47 drove a 15.2% post-print gap to a 52-week high $47.09 close on 2026-08-07 at RSI 86.9. The company's own Q3 guide (GM 35–37%, adj EBITDA margin 9–11%)…

Contested insurtech IPO reclaimed its $19 price in a late-June ~28% rip and has held it into a fresh JPM Overweight (PT $23, 2026-07-13). But the reclaim runs into the 2026-07-27 final lock-up and an unresolved upfront-accounting short…

Insider-cluster leg has already paid: Malone/Fries/Nair bought the post-distribution $4.98 June base, and the common is $7.34 — ~47% higher in under a month. July brought Citi's downgrade to Neutral (PT $8) and a Barclays Underweight at…

Post-catalyst drift: the $500M preferred special dividend and the June Malone/Nair insider cluster already drove a ~70% run off $4.76 to ~$8.30, and the tape has stalled at $7.33. Citi cut to Neutral 2026-07-10 with a $8 target already…

Deli prepared-foods roll-up keeps compounding — Q1 FY2027 (2026-06-08) revenue +49.7% YoY — but management top-ticked the 52-week high with a $100M raise at $18.00 (2026-06-30): ~14% dilution, momentum reset, theme cooling to maturing. No…

The June oil-tailwind cruise re-rating has matured and rolled over: July downgrades (Truist. Narrative velocity has reversed; the highest-beta name gives it back fastest.

Freight-cycle recovery in the top-margin LTL name is drawing a broadening upgrade cluster now printing above spot (Stifel $256 Jul 21, Truist $250 Jul 15, RJ $241 Jul 13), but growth is still rate and mix with tons/day negative. The…

Deep-cyclical carbon black where the 2024–25 tire-restock leg already failed (-32.5% from the $10.72 52-week high). What is left is a trough-and-deleverage read: Q2 2026 adj. EBITDA $58.2M (+26% sequential, -15% YoY), FY26 guide reaffirmed…

Reopening re-rate has matured: PK ground to a fresh 52-wk high ~$15 while the sell-side fades — Wells Fargo cut to Equal Weight $15, JPMorgan Underweight $13, Morgan Stanley $11, all at/below the tape. A fresh entry chases new highs at the…

Not a momentum name — a thinning merger spread. Skyworks buys Qorvo for $32.50 cash + 0.960 SWKS; with SWKS ~$61 the implied value is ~$90–93 against QRVO ~$88, leaving 3–4% for underwriting China SAMR. The 2026-07-28 Skyworks print…

Only year-long implantable CGM, clinically de-risked at ADA 2026 with revenue +71.9% YoY TTM — and the tape has spent six weeks grinding back toward the $4.79 post-catalyst low ($5.11 on Jul 17). Accelerating fundamentals against a broken…

Oral-GPCR platform narrative has cooled from accelerating to maturing: a marginal new high at $38.04 (2026-07-11) failed and the tape faded ~13% to $33.10 by 2026-07-24 into a catalyst vacuum. The first real binary (SEP-479 Phase 1) isn't…

April denifanstat/acne breakout round-tripped to the $6.00 Series A offering floor; SGMT bases near $7 (last close $7.06, 2026-06-26) with no trend. Dermatology pivot (China NMPA acne NDA accepted Dec 2025, US IND due mid-2026) is real but…

SI-joint-fusion medtech at a profitability inflection with a new Smith+Nephew pelvic-trauma distribution leg; tape has firmed to a base but stalls under the ~$17 200-day shelf it hasn't reclaimed. The confirmed 2026-08-03 Q2 print is the…

Specialty E&S compounder printing 20%+ operating ROE with the Apollo Lloyd's book integrated; the low-$40s-to-$63 re-rate is MATURING. The Aug 4 Q2 print is the next binary — a fresh chase near $60, up +17% in 30 days with earnings inside…

Freight-cycle recovery accelerating — all-mode tender rejections ~17% and dry-van spot ~$3.78/mi (highest since early 2022) — and SNDR has re-rallied to ~$38.5, near its $39.27 high, with analysts chasing (Morgan Stanley $45). The…

Busted-IPO thrift retailer's June recovery has stalled and rolled back toward its ~$9 base as the June 27 Russell-deletion passive-bid loss bites; the July 30 Q2 print is now an imminent, FX-exposed binary rather than a five-weeks-away…

Quality home-furnishings compounder in the consumer-discretionary rotation; Q1 (2026-05-21) reaccelerated every brand to positive comp and the revision cluster keeps building (KeyBanc raised to $250 on 07-07). At ~$226.74, ~7% under the…